Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 399-401, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-778894
ABSTRACT
The formation of cirrhotic portal hypertension depends on the increase in intrahepatic vascular resistance and the state of hyperdynamic circulation. The specific effect of carvedilol in reducing intrahepatic vascular resistance has a better effect in alleviating portal hypertension in theory. This article summarizes the known and possible mechanisms of carvedilol in reducing portal hypertension and reviews the latest research advances in the role of carvedilol in the treatment of cirrhotic portal hypertension. It is pointed out that carvedilol is expected to become the core drug in the treatment of cirrhotic portal hypertension, and statins may be their best partner.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Clinical Hepatology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS